Rating Change
Leerink Partners analysts initiated coverage on Vera Therapeutics, Inc. (NASDAQ:VERA) with a rating of Market Perform on October 12, 2026.
new coverageNASDAQ:VERA
Leerink Partners Initiates Coverage on Vera Therapeutics, Inc. (VERA) with Market Perform
Leerink Partners analysts initiated coverage on Vera Therapeutics, Inc. (NASDAQ:VERA) with a rating of Market Perform on October 12, 2026.
At publication ·
What changed
Vera Therapeutics, Inc. (NASDAQ:VERA) · new coverage
- Firm
- Leerink Partners
- Rating
- Market Perform
- Price at event
- $27.72
- Market capitalization
- $2.9B
At a glance
Key takeaways
- Leerink Partners initiated coverage of Vera Therapeutics (VERA) with a Market Perform rating on October 12, 2026.
- VERA trades at $27.72 with a $2.9B market capitalization in the healthcare sector.
- Among the 10 most recent analyst ratings, 6 are Buy and 4 are Hold with no Sell ratings.
- Analyst ratings and price targets are one input among many for investment decisions and have mixed predictive power.
Market Context
Vera Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $27.72 with a market capitalization of $2.9B.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Vera Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Vera Therapeutics, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 12, 2026 | Leerink Partners | Market Perform | N/A |
| Sep 08, 2026 | JP Morgan | Overweight | N/A |
| Aug 17, 2026 | Wedbush | Neutral | N/A |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 11, 2026 | Wedbush | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View VERA Stock Page
Frequently Asked Questions
What does the Market Perform rating mean for VERA?
A rating of Market Perform from Leerink Partners reflects the analyst's outlook on Vera Therapeutics, Inc. (NASDAQ:VERA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the VERA forecast page.
Loading related coverage…